DICE Therapeutics to Participate in the H.C. Wainwright Autoimmune &…
<!-- Name:DistributionId Value:8794599 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Nasdaq:DICE
DICE Therapeutics Reports Second Quarter 2022 Financial Results and Recent Highlights
Completed enrollment in Phase 1 clinical trial of lead oral IL-17 antagonist DC-806; topline proof-of-concept data in healthy volunteers and psoriasis patients expected in 2H 2022 SOUTH…
DICE Therapeutics Announces Completion of Enrollment in Phase 1 Clinical Trial of…
Topline proof-of-concept data in healthy volunteers and psoriasis patients expected in 2H 2022 SOUTH SAN FRANCISCO, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc.…
DICE Therapeutics Initiates Phase 1 Clinical Trial of S011806 for the Treatment of…
SOUTH SAN FRANCISCO, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build…